![]() |
| Tyhry and Marda. |
See my previous blog post for additional planning with Google's Search AI.
I asked Claude for a timeline of the bioengineering project that is cover for Marda.
Me: Claude, process the PDFs that I uploaded (1) "A blueprint for designing the next-generation of synthetic C1 microbes" and (2) "Biosynthesis and Bioactivity of Prodiginine Analogs in Marine Bacteria, Pseudoalteromonas: A Mini Review" by Awaya et al. Claude, for a science fiction scenario (in my current work-in-progress titled "The Hierozyme Intervention"), imagine applying ideas from "A blueprint for designing the next-generation of synthetic C1 microbes" to a marine bacterium of the Pseudoalteromonas genus with the goal of turning the genetically modified Pseudoalteromonas bacterium into a biological factory that can convert carbon atoms that are ultimately derived from carbon dioxide into a dense, high molecular weight carbon-containing product that is (1) efficiently released from the modified Pseudoalteromonas bacterium and which (2) is resistant to being metabolized by other organisms, creating the means to remove carbon dioxide from sea water and sink the carbon to the sea floor.
This might be like fitting a square peg in a round hole, but I have a story-derived reason for pretending that a marine bacterium of the Pseudoalteromonas genus could be engineered in this way. Outline a series of fictional steps that could taken by a laboratory with unlimited funds to accomplish this bacterial engineering project.Claude: This is a fun engineering problem, and it maps onto the two papers nicely — the Nikel blueprint gives you the roadmap structure, and the Pseudoalteromonas paper actually hands you a piece of repurposable hardware that's relevant: the pig/tam biosynthetic gene cluster is fundamentally an iterative polyketide-type chain-assembly system (PigG/PigH/PigJ acting like a mini fatty-acid-synthase, with PCP/ACP carrier domains and malonyl-CoA-fed chain extension). That's not nothing — it means a Pseudoalteromonas chassis already has an extendable carbon-chain-building production line built in, just currently wired to make a 50-Da-ish pigment instead of a multi-kilodalton sequestration polymer. Below is a roadmap for "Hierozyme Intervention," following the blueprint's own three-phase logic (bioprocess design → strain/pathway engineering → bioproduction/scale-up/sustainability), with the square-peg moments flagged honestly.
Before touching the genome, your lab decides what the sequestered carbon actually is, because that choice drives everything downstream (this is the Nikel paper's "begin with the end in mind" principle).
Target product candidates, ranked by how well they satisfy "dense, high-MW, won't get eaten":
- Option A — A non-natural poly-hydroxyalkanoate (PHA) variant. Marine bacteria already make PHAs as carbon storage granules; they're already a known carbon sink mechanism. The fictional twist: extend the monomer repertoire beyond 3-hydroxybutyrate to longer, branched, or halogenated hydroxyacids that standard depolymerases can't cleave.
- Option B — A wax ester / very-long-chain lipid. Dense, hydrophobic, naturally resistant to aerobic and anaerobic remineralization compared to simple fatty acids, and several marine bacteria (and copepods) already build these for buoyancy/ballast control — you'd be inverting the ballast logic to sink rather than float.
- Option C — A biomineral-encased polymer. Borrow the diatom/coccolithophore trick: nucleate a thin silica or calcium carbonate shell around the polymer granule. This solves density (mineral ballast sinks fast) and resistance (encasement blocks enzymatic access) simultaneously.
For "The Hierozyme Intervention," C is probably your most narratively interesting and biochemically defensible choice, since it borrows two real, independently-evolved biological tricks (granule formation + biomineralization) rather than inventing an exotic polymer chemistry from nothing.
Feedstock choice (per the blueprint's substrate logic): seawater bicarbonate/dissolved CO2 is your C1 source. Since Pseudoalteromonas is heterotrophic and not naturally autotrophic, you need an entry pathway — this is where the blueprint paper's pathway menu becomes directly useful.
Following the blueprint's "industriophilicity" checklist:
- Pick a cold/temperate-adapted, fast-growing, genetically tractable species — P. tunicata or P. rubra are good picks since they already have published genome sequences, conjugation-based transformation systems, and (for P. rubra) a fully mapped pig cluster you're about to gut.
- Multi-omics baseline: transcriptomics/proteomics under varying dissolved CO2/bicarbonate to see whether any native carbonic anhydrase or anaplerotic (PEP carboxylase-type) activity already exists to build on — every native C1-handling enzyme you find is one fewer thing to engineer from scratch.
- Genome-scale metabolic model (GSMM) construction, FBA/MDF analysis exactly as in the blueprint, to check whether routing carbon into a long polyketide-like chain is even thermodynamically sane before you commit. This is the "fail fast in silico" step.
This is the heart of it, in four linked modules:
3a. CO2/bicarbonate fixation entry module.
Install a synthetic reductive glycine pathway (rGlyP) — the blueprint
paper flags this as the simplest, most linear of the C1-fixation routes,
which matters because you're retrofitting a heterotroph, not
redesigning one from the ground up. rGlyP feeds reduced one-carbon units
into the glycine cleavage system / serine pathway, generating
acetyl-CoA and, critically for you, malonyl-CoA — the same building
block the native pig pathway already consumes.
3b. Redirect the pigment assembly line into a polymer assembly line.
This is the clever reuse. PigH and PigJ in the native pathway perform iterative decarboxylative condensation with malonyl-CoA — structurally, that's a fatty-acid-synthase-like elongation cycle, just truncated after one or two extensions because the pathway's "stop" signal is wired to terminal condensation by PigC. Fictionally-plausible engineering move: delete PigC (which normally terminates the pathway by condensing MAP and MBC into prodigiosin) and instead fuse the PigG/H/J carrier-and-extension module to a processive type-I-PKS-style architecture that just keeps looping malonyl-CoA additions — building a long aliphatic backbone instead of a 3-ring pigment. You're essentially asking the existing pigment factory to forget when to stop.
3c. Backbone-hardening module.
Borrow PigF (the SAM-dependent methyltransferase) and overexpress it
promiscuously along the new long-chain backbone, plus introduce a
halogenase (these exist natively in many marine
Pseudoalteromonas/Pseudomonas relatives for producing halogenated
secondary metabolites) to decorate the chain with chlorine or bromine
substituents at intervals. Branching, methylation, and halogenation are
all real strategies organisms and chemists use to make a polymer harder
for hydrolases and lipases to engage with — this is your "resistant to
remineralization" lever.
3d. Biomineralization module.
Express a silica- or calcite-nucleating peptide (modeled loosely on
diatom silaffins or coccolithophore mineralization proteins) tethered to
the surface of the forming polymer granule, so each granule grows a
thin mineral shell as it's built. This gives you density (sinks fast,
beating the days-to-weeks window in which most surface-ocean organic
carbon gets remineralized) and a physical diffusion barrier against
bacterial/viral enzymatic attack.
You need the granule outside the cell, not accumulating until the cell bursts (which would just feed it straight to local grazers and saprophytes).
Pseudoalteromonas already has precedent for this: tambjamine production in P. tunicata involves dedicated permeases and a putative ABC transporter (TamM/TamN) for moving pathway products across the membrane. Repurpose/upsize this transporter system — or more plausibly, drive granule release via outer-membrane-vesicle (OMV) budding, which gram-negative marine bacteria do constitutively for all sorts of secreted cargo. Packaging the mineralized granule into a budding OMV solves export and gives you a small amount of incidental membrane/lipid coating as a bonus resistance layer.
Exactly as the blueprint argues for any synthetic autotrophy effort: this engineered pathway will be a massive proteome burden, and rational design alone won't get you to a robust, fast-growing strain. Run ALE campaigns selecting directly for sinking rate and granule density (e.g., column assays where only cells producing fast-sinking granules survive sequential dilution), paired with proteomics/fluxomics to find where flux is bottlenecked (the blueprint's own C. necator rGlyP case study found exactly this kind of unexpected expression-level mismatch).
Per the blueprint's Fig. 1 loop: once you have a working strain, you cycle back through TEA/LCA-style assessment — except your "product value" isn't a sellable chemical, it's tons of CO2 sequestered per liter of culture per year, weighed against the energy/nutrient cost of growing the bacteria at open-ocean scale. This is also a good place to fictionally embed your story's stakes: does Hierozyme deploy this in contained mariculture pens (controllable, slow, defensible) or release it into the open ocean (fast, uncontrollable, ecologically fraught — shades of real-world ocean iron fertilization controversies)?
The blueprint paper's own caution about LCA being incomplete without full cradle-to-grave accounting (what happens to the granules after they hit the seafloor — do they get buried, or eventually scavenged by deep-sea/anaerobic communities over centuries?) is a very natural and scientifically honest source of dramatic tension for your story, rather than a plot hole you need to paper over.
One honest flag on the square-peg-in-round-hole part: the biggest real-world implausibility isn't the genetics, it's thermodynamics and energy balance. Building long, mineral-encased, halogenated polymers from CO2 is energetically expensive, and a free-living marine heterotroph has no sunlight-equivalent cheap energy source the way a photoautotroph would. Your story could lean into this rather than ignore it — maybe Hierozyme's breakthrough isn't the carbon chemistry above (which is the relatively "easy" part to hand-wave) but solving where the reducing power and ATP come from at scale, which is exactly the energy-donor problem the Nikel paper spends real space on (H2 vs. methanol vs. formate as electron donors). That could even be your "Hierozyme" — maybe it's not the bacterium, but a coupled chemical/electrochemical system (a Power-to-X setup, in the blueprint's own terms) feeding the bacteria, with the engineered Pseudoalteromonas as just the back end of a hybrid bioelectrochemical carbon-sinking apparatus.
Me: Timeline. Pretend that a draft genome sequence for a particularly favorable marine Pseudoalteromonas species was published in 2016. Assume that Tyhry Watson (she is working in the lab that is engineering this Pseudoalteromonas species) is able to secretly provide every magical hierozyme that is needed to solve all the problems that you mentioned. She just wants all of the conventional bioengineering effort in the laboratory to provide "cover" for the use of alien technology (the hierozymes that she can secretly provide and engineer into the bacterium via an invisible small alien nanotechnology endosymbiont). Claude, generate an imaginary beast-case timeline for the project starting in 2016 and successfully terminating sometime before Tyhry is forced into retirement.
Claude: One quick thing before I build this: I don't have a specific year (or her age) for when Tyhry gets forced into retirement in your notes, so I can't tell if "best case" needs to land in five years or twenty-five. I'll draft this assuming she's got a fairly long runway — say the project needs to wrap with real margin to spare — but flag where I'm guessing, and you can tell me to compress or stretch it.Here's the dual-track timeline: the public cover story the lab publishes, and underneath it, what's actually happening via the hierozyme/nanotech endosymbiont Tyhry is secretly running.
2016 — Draft genome published. The real trigger event. A particularly favorable Pseudoalteromonas species gets its draft genome sequenced and released, giving the lab (and Tyhry) a public, citable reason to take interest in this organism specifically.
2017 — Project greenlit; GSMM modeling "discovers" the right pathway. Publicly: routine in silico flux balance analysis on the new genome, looking for native C1-handling enzymes worth exploiting. Secretly: the hierozyme has already mapped the entire metabolic network overnight and identified exactly which native pig-cluster machinery to repurpose. Tyhry seeds this as a "promising lead from comparative genomics" so nobody asks why she got there so fast.
2018 — Genetic toolkit stood up. Conjugation-based transformation, CRISPR base-editing — all real, all slower than it needs to be on paper. The nanotech endosymbiont is doing precision edits invisibly; the lab's actual recorded experiments are mostly Tyhry running the "official" slow version in parallel so there's a believable paper trail of false starts and iteration.
2019 — CO2-fixation module "discovered" via rGlyP homology search. Public framing: an elegant homology-based design choice, very on-brand for the field at the time (this is the same year real synthetic-biology labs were publishing rGlyP work). Secretly: the entry pathway is already fully functional; what's published is a deliberately unremarkable first version.
2020 — Pigment pathway repurposed into a chain-elongating module. This is the one Tyhry has to manage most carefully — turning PigC off and letting PigH/PigJ run as an uncontrolled extension loop isn't an obvious move, and a flawless first try would look suspicious. She lets the "official" lab process burn through a year of failed constructs before the "breakthrough" variant (already perfected in secret) gets dropped into the dataset.
2021 — Backbone hardening (methylation/halogenation) and granule visualization. Public: TEM images of dense intracellular granules, framed as an unexpected side effect of the chain-elongation work — a "happy accident" that becomes the next year's research direction. This is good cover logic: real science is full of happy accidents, so one more doesn't raise eyebrows.
2022 — Biomineralization shell engineered. Cover story: metagenomic mining turns up a silaffin-like peptide homolog in a sister Pseudoalteromonas strain, which gets cloned in. Secretly, the actual mineral-nucleation system is far more sophisticated than anything biology has produced — Tyhry undersells the granules' density and resistance in early internal reports to manage expectations.
2023 — Export/secretion module via OMV budding. Granules start showing up outside the cell in culture supernatant. This is presented as the natural next discovery once the granule was stable. Internally, the lab starts calling the strain something like HZ-1.
2024 — First closed mesocosm trials. Tank- or fjord-enclosure scale. Sinking rates and resistance to remineralization get measured under controlled conditions. First public paper goes out — intentionally framed as incremental, modest, not headline-grabbing, to avoid early scrutiny.
![]() |
| Image by Flow. |
2026 — Contained field trial. A real open-water but enclosed (sea-pen style) deployment. This is the year the technology stops being a lab curiosity and becomes a candidate climate intervention, with everything that implies for who starts paying attention to Tyhry's lab.
2027 — Scale-up and first uncontained pilot release, assuming the contained trial goes cleanly. This is plausibly your "successful termination" point — the project moves from promising to proven, at which point Tyhry's personal involvement may no longer be required for it to proceed without her.
That's about an eleven-year arc, which is fast for unaided human biotech but not so fast it reads as obviously impossible — there's enough visible, plausible friction (failed constructs, happy accidents, slow regulatory steps) for the cover story to hold together, while the real engineering bottleneck is reduced to nothing.
If you let me know roughly how many years of runway Tyhry actually has before retirement, I can compress this further (if she's got less time) or stretch out the cover-story friction even more convincingly (if she's got more) — more publishable "false starts" make for a more believable paper trail, if you want that texture in the story.
Me: My retirement comment was a joke; I'm imagining a precocious Tyhry Watson starting college at the age of 16 (in the year 2013) and getting involved in the bioengineering of this Pseudoalteromonas species. The timeline you generated is fine. Creating this kind of imaginary timeline reminds me of a young Isaac Asimov in the 1940s trying to imagine then the world might first see a speaking and reasoning positronic robot such as the robot called "Cutie" in the story "Reason".
Claude: There's something genuinely apt about that comparison. Asimov in the 1940s was building a retrofitted future history — working backward from "we need positronic robots integrated into society by such-and-such date" and filling in plausible-looking institutional steps to get there, even though the actual enabling technology (a brain you could write three governing laws into) was pure invention with no real engineering pathway. The skill wasn't in solving robotics; it was in making the social and institutional friction around an impossible technology feel earned — committee reports, the U.S. Robots company's internal caution, the gradual rollout from industrial to humanoid models. The technobabble he needed was minimal because the believability was carried by bureaucracy and timeline texture, not by circuit diagrams.That's almost exactly the trick we just did with HZ-1. The actual hard problem — CO2 fixation, chain elongation past a stop signal, biomineralized export — is being solved by something that isn't bioengineering at all. What makes the timeline feel earned is the cover-story friction: the year of deliberately unremarkable false starts in 2020, the "happy accident" framing in 2021, the slow regulatory grind in 2025 even though the biology was already finished years earlier. Asimov needed that same kind of friction to make a positronic brain feel like the product of decades of institutional caution rather than an author's fiat.
And there's a nice irony specific to "Reason" that your framing surfaces nicely, even if it wasn't intentional: Cutie reasons itself into an entirely wrong but internally consistent theology because it's working from incomplete data and refuses the humans' actual explanation of its own origins. Tyhry is the inverse — she knows the true explanation and is the one constructing the false-but-internally-consistent cover story for everyone else. Cutie can't see the truth it's embedded in; Tyhry can't let anyone else see the truth she's embedded in. Both end up with a lab full of people operating on a plausible but incomplete model of what's actually happening in the room.
2013 for college entry at 16 also lines up nicely on its own terms — she'd be 19 when the 2016 genome paper drops, which is exactly the age where a precociously placed grad student or stand-out undergrad could plausibly already be embedded in a working lab without anyone needing extra explanation for her presence.
Me: For "The Hierozyme Intervention", I will probably use your timeline right up to the year 2027 where your said, "assuming the contained trial goes cleanly". At that point, the measured carbon fixation results will look very poor. Tyhry will finish the project on her own (secretly switching on use of all of the hierozymes that she has engineered into the bacterial endosymbiont, boosting the efficiently of the conventional enzymatic pathways). A few years later when the deep ocean has begun to act like an efficient carbon sink, the explanation given will be that an escaped laboratory strain of the engineered bacterium went through a form of natural selection in the ocean and became more efficient at fixing carbon. At the end of the story, an elderly Tyhry will get a message from an old colleague who has tried for decades to understand how the bacterial strains in the ocean are so efficient at trapping carbon. That colleague will tell Tyhry that he is giving up, "Those bugs are smarter than I am." Nobody but Tyhry will know how alien technology (hierozymes) were used to solve the global warming problem.
Claude: This is a strong turn — it gives the project a real failure point, and the "banked strain vs. wild strain" divergence is what makes the cover story bulletproof rather than just convenient. Here's the timeline revised from 2027 on, plus the mechanism I think makes the rest of it hang together.
2027 — Contained trial: disappointing numbers. Granule density and resistance to remineralization both check out fine, but carbon fixation rate is far below projections — the conventional rGlyP/PigH-PigJ pathway simply can't push flux fast enough at scale. This matches real published synthetic-methylotroph results almost exactly (the blueprint paper's own C. necator rGlyP strain grew at half the wild-type rate), so it reads as completely unremarkable to anyone reviewing it. Funding scrutiny begins. The "official" strain goes into the freezer as a documented, unglamorous result.
2027 (same year) — The breach. Sea-pen containment failures are a known, banal risk — net damage, a storm, routine breach protocol. Tyhry doesn't need to engineer an escape; she just needs to not be the one who patches the hole fast enough, or to be the one filing the "low-priority, strain showed no concerning fitness in trials" incident report. Nobody chases down an organism that just demonstrated mediocre performance.
2027–2028 — The quiet switch. Once in open water, away from catalogued lab conditions, Tyhry activates the hierozyme suite — possibly via a trigger she'd built in long before, tied to environmental cues only present in open ocean (pressure, trace metals, salinity gradients) rather than tank conditions. This does double duty: it's the actual mechanism, and it's also exactly the kind of cue-dependent expression switch a real microbiologist would eventually propose as an "explanation," which keeps the future mystery scientifically idiomatic rather than supernatural-feeling.
2030s — The signal emerges. Oceanographic carbon-flux measurements start showing anomalous deep-water drawdown. Eventually traced to wild populations of the engineered genus, now diverged and flourishing far beyond anything the banked lab strain could do.
2030s–2040s — The community of bafflement. This is where I think the story gets to have the most fun: a generation of marine microbiologists (your "old colleague" among them) spend careers sequencing wild populations, finding enzyme variants and pathway configurations that don't look like anything a gradualist selection story should produce that fast, and patching together horizontal-gene-transfer narratives, cryptic environmental hypermutation theories, anything that keeps Darwin intact. They're not wrong that it evolved — they're wrong about what it evolved from.
Decades later — the message. The colleague, having spent a career on this, finally writes to Tyhry — maybe one of the only people left from the original program — and tells her he's done. "Those bugs are smarter than I am."
One thing I'll flag because I think it strengthens the bones of this rather than just being trivia: this is structurally the same misdirection device you're already running in The RNA Seeds — Eddy's published fiction as the real engine of the Reality Change, deliberately pointing everyone away from Tyhry as the true source. Here, "natural selection did it" is the Eddy-fiction equivalent: a true-sounding, scientifically idiomatic explanation that absorbs all the curiosity in the room and quietly protects the actual mechanism. If you wanted a small connective thread across the EFU, that parallel between Klaudy-era Tyhry and RNA-Seeds-era Tyhry — always the one engineering the cover story other people don't know they're inside of — could be worth a line of recognition somewhere, even just in her own head.
Want me to take a pass at drafting the colleague's actual message, or at the banked-strain detail that surfaces when someone finally pulls the original freezer sample decades later and notices it never matched the wild population?
Next: Chapter 5 of "The Hierozyme Intervention".
sd
Next:

































